Chemoradiotherapy of NSCLC Stage IIIB

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the best timing of the concomitant chemoradiotherapy among patients with NSCLC stage III not resectable treated by concomitant chemo-radiotherapy, either preceded by a induction chemotherapy, or followed by a consolidation chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique
• Collaborators: Bristol-Myers Squibb; Ligue contre le cancer, France; Pierre Fabre Laboratories
• Treatments: Paclitaxel; Vinorelbine

Criteria

Inclusion Criteria:

• NSCLC stage IIIA N2 or IIIB not resectable, except N3 sus-clavicular, nor reached pleural

• PS = 0 or 1

• Possibility of including all the targets in only one exposure field

• Slimming < 10% of the weight of the body

• Functions hepatic, renal and hematologic normal

• VEMS >40% and PaO2 >60 mmHg

• written and signed informed consent

Exclusion criteria :

• NSCLC stage IV or wet-IIIB